

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



alpha Smooth Muscle Actin Recombinant Monoclonal Antibody [BLR082G]



Rabbit Recombinant Monoclonal

Purified RefSeg ID NP_001135417.1

Catalog No. A700-082CF Uniprot ID P62736

Lot No. A700-082CF-2

AMOUNT 100 μl

CONCENTRATION 1000 μg/ml

STORAGE/SHELF LIFE 2 - 8°C / 1 year from date of receipt

PHYSICAL STATE Liquid

BUFFER Borate Buffered Saline (BBS) pH 8.2 with 0.09% Sodium Azide, BSA Free

ISOTYPE IgG

CLONE # BLR082G
ORIGIN USA

PRODUCTION PROCEDURES

Recombinant antibody was purified from cell culture supernatant.

Immunogen was a peptide representing a region between residue between 1 and 50 of human aortic smooth muscle actin using the numbering given in entry NP_001135417.1

(Gene ID 59).

APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be determined

experimentally by the investigator. Prepare working dilution immediately before use.

A700–082CF is the carrier–free version of RMAB1243–2C4, which is qualified for use in Western Blot, Immunoprecipitation, Immunohistochemistry, and/or Immunocytochemistry. The format of A700–082CF is designed for compatibility with the labeling of the antibody

such as with fluorochromes, metal isotopes, oligonucleotides, and enzymes. Upon completion of labeling, the user must empirically define the assay dependent concentration

for use.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.

Michael Spencer, PhD

Date: November 15, 2022